Researcher profile

Kevin L. Moore

Kevin L. Moore contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
3topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Strong Sign Controllability of Diffusively-Coupled Networks

This paper presents several conditions to determine strong sign controllability for diffusively-coupled undirected networks. The strong sign controllability is determined by the sign patterns (positive, negative, zero) of the edges. We first provide the necessary and sufficient conditions for strong sign controllability of basic components, such as path, cycle, and tree. Next, we propose a merging process to extend the basic componenets to a larger graph based on the conditions of the strong sign controllability. Furthermore, we develop an algorithm of polynomial complexity to find the minimum number of external input nodes while maintaining the strong sign controllability of a network.

preprint2021arXiv

Knowledge-Based Three-Dimensional Dose Prediction for Tandem-And-Ovoid Brachytherapy

Purpose: To develop a knowledge-based voxel-wise dose prediction system using a convolution neural network for high-dose-rate brachytherapy cervical cancer treatments with a tandem-and-ovoid (T&O) applicator. Methods: A 3D U-NET was utilized to output dose predictions using organ-at-risk (OAR), high-risk clinical target volume (HRCTV), and possible source locations. A sample of previous T&O treatments comprising 397 cases (273 training:62 validation:62 test), HRCTV and OARs (bladder/rectum/sigmoid) was used. Structures and dose were interpolated to 1x1x2.5mm3 dose planes with two input channels (source positions, voxel identification) and one output channel for dose. We evaluated dose difference (ΔD)(xyz)=D_(actual)(x,y,z)-D_(predicted)(x,y,z) and dice similarity coefficients in all cohorts across the clinically-relevant dose range (20-130% of prescription), mean and standard deviation. We also examined discrete DVH metrics used for T&O plan quality assessment: HRCTV D_90%(dose to hottest 90% volume) and OAR D_2cc, with ΔD_x=D_(x,actual)-D_(x,predicted). Pearson correlation coefficient, standard deviation, and mean quantified model performance on the clinical metrics. Results: Voxel-wise dose difference accuracy for 20-130% dose range for training(test) ranges for mean (ΔD) and standard deviation for all voxels was [-0.3%+/-2.0% to +1.0%+/-12.0%] ([-0.1%+/-4% to +4.0%+/-26%]). Voxel-wise dice similarity coefficients for 20-130% dose ranged from [0.96, 0.91]([0.94, 0.87]). DVH metric prediction in the training (test) set were HRCTV(ΔD_90)=-0.19+/-0.55 Gy (-0.09+/-0.67 Gy), bladder(ΔD_2cc)=-0.06+/-0.54 Gy (-0.17+/-0.67 Gy), rectum(ΔD)_2cc=-0.03+/-0.36 Gy (-0.04+/-0.46 Gy), and sigmoid(ΔD_2cc)=-0.01+/-0.34 Gy (0.00+/-0.44 Gy). Conclusion: 3D knowledge-based dose predictions for T&O brachytherapy provide accurate voxel-level and DVH metric estimates.